Monitoring hub

Compounded Rx Public Data and Downloads

Pharmacy; license; inspection; recall; warning letter; medication; state; relationship; methodology datasets.

What is established about pharmacy?

For compounding pharmacy data, pharmacy is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where pharmacy has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about license?

For compounding pharmacy data, license is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where license has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about inspection?

For compounding pharmacy data, inspection is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where inspection has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about recall?

For compounding pharmacy data, recall is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where recall has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about warning letter?

For compounding pharmacy data, warning letter is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where warning letter has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What does this page establish?

It establishes the framework and the source map for compounding pharmacy data, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.

What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.

Status terms on this page follow the platform's published status vocabulary.

Why compounding pharmacy data is hard to verify

Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.

First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.

That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.

What this currently costs

Price is one of the few variables a reader can act on directly, so it is reported here rather than left to a separate page. Among the programmes this platform has verified by recomputation, the lowest regular injection rate is $145 per month on the longest commitment tier (NexLife), against higher rates on shorter terms.

Every tier behind that figure was recomputed from the published total rather than taken from the advertised per-month rate — 16 of 18 reconcile exactly, and the two that do not are published with the corrected figure on the regular injection affordability page.

The economic case has changed

During the shortage, compounded preparations undercut the approved products by a wide margin, and that price gap was the entire consumer proposition. It is the part of the market that has changed most.

Zepbound self-pay through the manufacturer's direct channel now runs $299 per month at the starting dose and $449 at maintenance doses, against a retail list price near $1,086. The gap between compounded pricing and the manufacturer's cash channel is far narrower than it was in 2023.

For a buyer, that changes the calculation: the residual risk of an unapproved preparation with no premarket review is being accepted for a smaller and smaller discount.

Related records in this section

Section hub: Monitoring hubs · Methodology · Status definitions · Right to respond

Sources

• FDA — Information for Outsourcing Facilities
• FDA — Q&A: Outsourcing Facility Registration
• FDA — Registered Outsourcing Facilities
• FDA — Aligning Federal and State Regulation of Compounders
• FDA — Outsourcing Facility Fees
• FDA — Compounded Drug Products That Are Essentially Copies
• FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
• FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
• Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
• FDA — Outsourcing Facility Fees guidance

Update history

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.